A high blood cholesterol concentration is the most important risk factor for cardiovascular disease which is the most common cause of death worldwide. Currently, doctors take a trial-and-error approach in determining the optimal cholesterol-lowering therapy.
“However, this can take years and it leaves many patients at high residual risk for cardiovascular disease,” says Tamara Alagirova from the Moncyte team out of the University of Helsinki. The Moncyte team includes also Simon Pfisterer, Iryna Hlushchenko and Valeria Ullrich.
Moncyte has come up with a solution that provides insight into the cellular mechanisms underlying cholesterol-lowering drug activity in individual patients.
“This tool opens up new ways for personalized medicine approaches in cholesterol treatment, helping more patients achieve their cholesterol target levels at an earlier time. This will save time and prevent life-threatening complications such as heart attacks and strokes,” Simon Pfisterer says.
This tool opens up new ways for personalized medicine approaches in cholesterol treatment.